TABLE 3.

Patient or Surrogate Participation in End-of-Life Discussions, Treatments Received, and Timing of Advanced Care Planning Among Patients With Documented Decision-Making Capacity on Admission

	Patients With Documented Decision-Making Capacity on Admission (N = 115)
	End-of-Life Discussion With Surrogate (N =46)	End-of-Life Discussion With Patient (N = 56)
	N (%)	N (%)	P Value
Life-Prolonging Treatment
Ventilatory support	26 (56.5)	13 (23.2)	<0.01
Chemotherapy	18 (39.1)	3 (5.4)	<0.01
Artificial nutrition or hydration	21 (45.7)	14 (25.0)	0.03
Antibiotics	45 (97.8)	44 (78.6)	<0.01
Cardiopulmonary resuscitation	7 (15.2)	4 (7.1)	0.19
ICU treatment (admit or transfer)	26 (56.5)	13 (23.2)	<0.01
Palliative Treatments
Comfort care	39 (84.8)	45 (80.4)	0.56
Palliative morphine drip	24 (52.2)	33 (57.1)	0.62
	Mean (95% CI) [Range]	Mean (95% CI) [Range]
Timing of Advanced Care Planning
Length of hospitalization	15.8 d (11.4–20.2) [1–57]	10.3 d (1–46) [1–46]	0.03
Time to end-of-life discussion	14.0 d (9.9–18.1) [0–55]	6.1 d (3.8–8.4) [0–46]	<0.01
Time to comfort care	23.5 d (4.3–42.8) [1–374]	9.2 d (6.3–12.1) [0–46]	0.12

Abbreviations: CI, confidence interval; ICU, intensive care unit.

^*P value is for comparison of end-of-life discussion with surrogate vs end-of-life discussion with patient.